Cardiovascular Effects of Asymmetric Dimethylarginine * Response
نویسندگان
چکیده
منابع مشابه
Cardiovascular effects of asymmetric dimethylarginine.
Asymmetric Dimethylarginine To the Editor: Kielstein et al1 describe the effects of the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine (ADMA), in humans in vivo but do not make reference to two previous human studies.2,3 In the original paper describing the presence of ADMA in human plasma and its accumulation in chronic renal failure, Vallance et al2 also described the...
متن کاملBiological Functional Relevance of Asymmetric Dimethylarginine (ADMA) in Cardiovascular Disease
There is growing evidence that increased levels of the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) may contribute to endothelial dysfunction. Studies in animal models as well as in humans have suggested that the increase in ADMA occurs at a time when vascular disease has not yet become clinically evident. ADMA competitively inhibits NO elaboration by displacing L-arginin...
متن کاملResponse to "Asymmetric dimethylarginine and DDAH1 transcript variants in cardiovascular and cerebrovascular diseases".
To the Editor: We read with great interest the article “Correlations of DDAH1 Transcript Variants With Human Endothelial Asymmetric Dimethylarginine Metabolizing Activity”1 by Sun and colleagues, which deals with the relationship between the activity of asymmetric dimethylarginine (ADMA; an endogenous nitric oxide synthase inhibitor) and its degradation enzyme (dimethylarginine dimethylaminohyd...
متن کاملAsymmetric dimethylarginine and asthma.
ADMA, a product of protein degradation, is an endogenous nitric oxide synthase inhibitor that has been shown to be increased in mouse models of allergic airway inflammation and to be associated with airways hyperresponsiveness in these animals [2]. ADMA has also been reported to be increased in sputum samples [2] and exhaled breath condensates [3] from paediatric patients with asthma. Increased...
متن کاملResponse to letters regarding article, "unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine".
BACKGROUND Proton pump inhibitors (PPIs) are gastric acid-suppressing agents widely prescribed for the treatment of gastroesophageal reflux disease. Recently, several studies in patients with acute coronary syndrome have raised the concern that use of PPIs in these patients may increase their risk of major adverse cardiovascular events. The mechanism of this possible adverse effect is not known...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2004
ISSN: 0009-7322,1524-4539
DOI: 10.1161/01.cir.0000132733.11967.eb